Authors: Singh, Hariom¹; Sachan, Rekha²; Jain, Meenu¹; Mittal, Balraj¹

Source: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Volume 17, Number 2, 2008 , pp. 87-91(5)

Publisher: Cognizant Communication Corporation

Abstract:

Inflammation plays a major role in the pathogenesis of cervical cancer. Chemokines are involved in inflammation, cancer, and infectious diseases. Therefore, we evaluated the association of the chemokine receptor gene polymorphism CCR5 Δ32 with risk of cervical cancer. A total of 150 histopathologically confirmed patients with cervical cancer and 162 age and ethnically matched cervical cytology negative healthy controls were genotyped for CCR5 Δ32 polymorphisms using PCR. Association of CCR5 Δ32 genotypes with risk of cervical cancer, clinical stages, and tobacco exposure was analyzed using chi-square statistical tests. The frequency of the mutant allele CCR5 Δ32 was higher in patients with cervical carcinoma (2.3%) but there was no statistically significant difference (OR = 1.51; p = 0.685;). Association of CCR5 genotypes with clinical phenotypes showed significant risk with stage IB patients due to CCR5+/Δ32 genotype (OR = 4.43; p = 0.021). Furthermore, patients with CCR5+/Δ32 genotype and tobacco usage were at risk of cervical cancer (OR = 1.73, 95% CI = 0.27-1.28). In summary, CCR5 heterozygous genotype (+/Δ32) may significantly influence the early stage of cervical cancer development. However, the cervical cancer risk due to tobacco usage was not significantly modulated after interaction with CCR5+/Δ32 genotype.

Keywords: Cervical cancer; Chemokine receptor; Genetic polymorphism; Genetic susceptibility

Document Type: Research article

Affiliations: 1: Department of Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow-226014, India 2: Department of Obstetrics and Gynecology, Chatarapati Sahuji Maharaj Medical University, Lucknow, India

Publication date: 2008-02-01

More about this publication?

• Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
  Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.

Related content

• In this: publication
• By this: publisher
• In this Subject: Oncology
• By this author: Singh, Hariom ;  Sachan, Rekha ;  Jain, Meenu ;  Mittal, Balraj

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers